There has been a lot of publicity and debate recently over the benefits of running barefoot versus running in running shoes. Some of the debates have been interesting to follow with a lot of misinformation and misinterpretation of the the research. Barefoot runners have been widely touting some questionable research on barefoot running and been responding negativly to challenges of their belief in barefoot running.

Obviously in this context, barefoot is not a good idea for those with diabetes. The high risk for foot complications when weight bearing, especially in the presence of neuropathy means that footwer is essential for this population to protect the foot from damage. Doing otherwise or recommending otherwise is irresponsible.

More on the barefoot running debate and the techniques of barefoot running.

A reduction in bone mineral density is know to be a problem in those with Charcot’s neuroarthropathy. A reccent study by Christensen et al (Bone mineral density in diabetes mellitus patients with and without a Charcot foot) investigated 49 people with diabetes, of which 24 had a charcot’s foot. They compared bone mineral desnity at the calcaneus, hip and spine. Differences were found in the calcanues between the charcot’s group and teh cpntrol group, but no differences at the hip and spine. This suggest that the reduction in bone mineral density seen in charoct’s foot is a local phenomenon rather than a general problem.

More on Charcot’s Foot

News from Diabetes UK:

A new understanding and possible treatment for Type 2 diabetes could be on its way after one of the largest genetic studies to date discovered nine new genes linked to the condition.

The genes and blood glucose levels of over 120,000 volunteers were studied by scientists from 174 research centres across the world. A set of genes that control the body’s response to glucose in the blood was identified.

“An incredibly important finding”

“This is an incredibly important finding,” said Jim Wilson, a geneticist from Edinburgh University involved in the study.

“The discovery of these new genes influencing blood sugar levels is the first step on the important journey to developing new therapies for diabetes.”

A drug to prevent Type 2 diabetes?

“It opens up a whole new area of research to find which proteins are ‘druggable’. Genetics is like a can-opener: it allows us to get inside and understand what’s going on.”

The study’s scientists hope that in five to 10 years they will be able to identify which people have a genetic susceptibility to Type 2 diabetes, and to have a drug available that can prevent the condition developing.

The FDA announced today that they have approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

Here are some snippets from the press release:

Victoza is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas make more insulin after eating a meal.

Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It is not recommended as initial therapy in patients who have not achieved adequate diabetes control on diet and exercise alone.